<DOC>
	<DOCNO>NCT00655122</DOCNO>
	<brief_summary>The primary objective study clinical benefit dalteparin sodium thromboprophylaxis primary care medical subject . The secondary objective pharmacoeconomic evaluation hromboprophylaxis dalteparin sodium primary care medical subject .</brief_summary>
	<brief_title>Prophylaxis In Venous Thromboembolism In Primary Care , A Pilot Study</brief_title>
	<detailed_description>The study prematurely terminate December 9 , 2003 . The reason early termination relate safety efficacy issue . It relate difficulty recruiting patient .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Age &gt; 65 year Confinement bed 3 day , due : Heart failure Exacerbated chronic obstructive pulmonary disease Acute rheumatic involvement Written inform consent 1 . Cancer 2 . Anticoagulant treatment previous 3 month 3 . Stroke major surgery previous 3 month 4 . Systolic pressure &gt; 200 mmHg diastolic pressure &gt; 120 mmHg 5 . Known chronic hepatopathy 6 . Active hemorrhage site previous 3 month 7 . Active peptic ulcer 8 . Bacterial endocarditis 9 . Conditions increase risk hemorrhage 10 . Known coagulation disorder 11 . Hypersensitivity heparin HIT 12 . Life expectancy le 3 month 13 . Previous confinement bed 3 day</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>